Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT04935125 Completed - Asthma Clinical Trials

The Effects of Endurance and Strength Training in Subjects With Asthma

Start date: April 13, 2021
Phase: N/A
Study type: Interventional

Emerging evidence suggests that regular exercise can complement medical treatment for asthma. Furthermore there are no specific recommendation on how plan exercise training. To the best of current knowledge, there isn't enough evidence of the effect of a strength training in subjects with asthma. Therefore the aim of this study is to evaluate the short and long term effects of a strength and endurance training compared with endurance training alone in subjects with asthma.

NCT ID: NCT04933383 Completed - Asthma Clinical Trials

Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics

BOREAS
Start date: July 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild asthma. Both treatments will be administered by nebulization.

NCT ID: NCT04932551 Recruiting - Asthma Clinical Trials

Perspectives and Management of Atypical Asthma

Start date: January 15, 2021
Phase:
Study type: Observational

To evaluate the awareness/knowledge, clinical practice of atypical asthma among respiratory specialists and primary care practitioners (PCPs) in China.A total of 1166 respiratory specialists and 799 PCPs participated in the questionnaire survey via WeChat. The questionnaire included six major items, divided into physician demographic characteristics, awareness, diagnosis, medication prescription, assessment/education, and proposal.

NCT ID: NCT04928638 Not yet recruiting - Asthma Clinical Trials

Educational Intervention for Asthmatic and Allergic Patients

Start date: June 12, 2021
Phase: N/A
Study type: Interventional

Despite its importance, there are few studies that implement the use of new technologies in the approach to patients with asthma and allergy. Therefore, the objective of this study is to evaluate the effectiveness of a telematic educational intervention in patients with allergies and / or asthma

NCT ID: NCT04927195 Completed - Asthma Clinical Trials

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Start date: February 23, 2021
Phase: Phase 1
Study type: Interventional

This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.

NCT ID: NCT04924478 Not yet recruiting - Clinical trials for Asthma; Eosinophilic

Evaluation of Volatile Organic Compounds in Mepolizumab Therapy

EVOC4M
Start date: July 2021
Phase:
Study type: Observational

This study will recruit patients who are being prescribed Mepolizumab as part of their standard clinical care for the treatment of severe eosinophilic asthma. Over the course of their treatment, research data (questionnaires) and research samples (blood, breath and urine) will be collected in parallel to standard clinical measurements. The data and samples will be investigated to help better understand how Mepolizumab works, why it doesn't work in certain patients and why it works very well in others. This will help prescribers better identify patients that will benefit from Mepolizumab.

NCT ID: NCT04923607 Not yet recruiting - Clinical trials for Asthma Severe Persistent Controlled

Phase I Clinical Trial of TQC2731 Injection

Start date: June 25, 2021
Phase: Phase 1
Study type: Interventional

This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.

NCT ID: NCT04919265 Recruiting - Asthma Clinical Trials

Mother-Infant Cohort Study in Malaysia and China

Start date: June 3, 2022
Phase:
Study type: Observational

This mother-infant cohort study aims to determine the geographic differences in the microbial profiles in breast milk from mothers living in Malaysia and China that are potentially important determinants of infant development. It also aims to determine the impact of gut microbiome on infant health (temperament, gastrointestinal symptoms, eczema symptoms, and asthma symptoms).

NCT ID: NCT04918394 Completed - Asthma in Children Clinical Trials

Mold Exposure and Impact on Asthma Control in French Asthmatic Children

CHAMPIASTHMA
Start date: June 10, 2020
Phase:
Study type: Observational

Observational, multicenter, study conducted in 12 hospitals in the Nord and Pas-De-Calais departments. The aim of this study is to describe the relationship between reported exposure to molds and asthma control in a pediatric population. Each patient followed by a specialized asthma pediatrician in one of the study center will be proposed to participate in the study. Children aged 1 to < 18 years, with asthma diagnosis, based on the assessment of a specialized physician after a follow-up of at least 6 months Inclusion, non-inclusion and exclusion criteria will be verified by the investigators. The questionnaires will be completed during the consultation, collected by the physician in charge of the consultation and sent to the principal investigator for data entry. Inclusion will take place over a period of 12 consecutive months from the date of obtaining regulatory approval.

NCT ID: NCT04914078 Recruiting - Severe Asthma Clinical Trials

Severe Asthma Exacerbations and Mepolizumab Treatment

ESAM-BIO
Start date: September 21, 2021
Phase:
Study type: Observational

This is a hypothesis-generating project to investigate a) infective etiology and b) inflammatory profile of the exacerbations of asthma in severe asthmatic patients treated with the humanized monoclonal antibody against interleukin-5 Mepolizumab. Under these treatment conditions the study will inform on the relationship between these two axes: infection & innate immunity Vs inflammatory profile changes occurring during exacerbation events. In addition, the study will also explore the effect of Mepolizumab treatment on airway microbial composition and on airway/systemic immune response both at stable state and at the exacerbation.